For more information call (888) LUHS-888.
Kathy S. Albain
Women ages > 18 years old with the following criteria may be eligible: ECOG performance status 0 or 1; the tumor must be unilateral-invasive adenocarcinoma of the breast on histologic examination; HER2 status must indicate that the tumor is HER2-low; the patient must have undergone either a total mastectomy or breast-conserving surgery (lumpectomy). Additional requirements are in the protocol
The main purpose of this study is to learn if adding a targeted therapy, trastuzumab, to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning.